Morgan Stanley Anixa Biosciences Inc Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Anixa Biosciences Inc stock. As of the latest transaction made, Morgan Stanley holds 21,403 shares of ANIX stock, worth $89,464. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,403

Previous 33,325 35.77%

Holding current value

$89,464

Previous $95,000 26.32%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$2.38 - $3.75 $28,374 - $44,707	-11,922 Reduced 35.77%	21,403 $70,000
Q1 2025 May 15, 2025	BUY	$2.13 - $3.29 $3,352 - $5,178	1,574 Added 4.96%	33,325 $95,000
Q4 2024 Feb 14, 2025	SELL	$2.48 - $3.97 $372 - $595	-150 Reduced 0.47%	31,751 $78,000
Q3 2024 May 14, 2025	SELL	$2.21 - $3.48 $5,746 - $9,048	-2,600 Reduced 7.54%	31,901 $100,000
Q3 2024 Nov 14, 2024	SELL	$2.21 - $3.48 $5,746 - $9,048	-2,600 Reduced 7.54%	31,901 $100,000
Q2 2024 May 14, 2025	BUY	$2.21 - $3.35 $6,077 - $9,212	2,750 Added 8.66%	34,501 $76,000
Q2 2024 Oct 17, 2024	SELL	$2.21 - $3.35 $5,823 - $8,827	-2,635 Reduced 7.1%	34,501 $76,000
Q2 2024 Aug 14, 2024	SELL	$2.21 - $3.35 $5,823 - $8,827	-2,635 Reduced 7.1%	34,501 $76,000
Q1 2024 Oct 17, 2024	BUY	$3.08 - $5.02 $8,115 - $13,227	2,635 Added 7.64%	37,136 $115,000
Q1 2024 Aug 16, 2024	BUY	$3.08 - $5.02 $2,042 - $3,328	663 Added 1.82%	37,136 $115,000
Q1 2024 May 15, 2024	BUY	$3.08 - $5.02 $2,042 - $3,328	663 Added 1.82%	37,136 $115,000
Q4 2023 Aug 16, 2024	BUY	$2.85 - $4.19 $5,620 - $8,262	1,972 Added 5.72%	36,473 $141,000
Q4 2023 Feb 13, 2024	SELL	$2.85 - $4.19 $1,105 - $1,625	-388 Reduced 1.05%	36,473 $141,000
Q3 2023 Nov 15, 2023	SELL	$2.97 - $3.87 $11,880 - $15,480	-4,000 Reduced 9.79%	36,861 $120,000
Q2 2023 Aug 14, 2023	SELL	$3.0 - $5.97 $5,862 - $11,665	-1,954 Reduced 4.56%	40,861 $130,000
Q1 2023 May 15, 2023	SELL	$3.86 - $5.0 $36,538 - $47,330	-9,466 Reduced 18.11%	42,815 $184,000
Q4 2022 Feb 14, 2023	SELL	$3.78 - $5.81 $30 - $46	-8 Reduced 0.02%	52,281 $222,000
Q3 2022 Nov 14, 2022	SELL	$2.81 - $6.15 $5,549 - $12,146	-1,975 Reduced 3.64%	52,289 $257,000
Q2 2022 Oct 27, 2022	SELL	$2.55 - $4.1 $32,772 - $52,693	-12,852 Reduced 19.15%	54,264 $166,000
Q2 2022 Aug 15, 2022	SELL	$2.55 - $4.1 $32,772 - $52,693	-12,852 Reduced 19.15%	54,264 $166,000
Q1 2022 Oct 27, 2022	BUY	$2.5 - $3.42 $32,130 - $43,953	12,852 Added 23.68%	67,116 $184,000
Q1 2022 May 13, 2022	BUY	$2.5 - $3.42 $31,435 - $43,003	12,574 Added 23.05%	67,116 $184,000
Q4 2021 Feb 14, 2022	BUY	$2.88 - $5.5 $32,627 - $62,309	11,329 Added 26.22%	54,542 $162,000
Q3 2021 Nov 15, 2021	BUY	$3.57 - $5.6 $154,270 - $241,992	43,213 New	43,213 $206,000

Others Institutions Holding ANIX

# of Institutions

Shares Held

5.33M

Call Options Held

14.1K

Put Options Held

12.1K

View Full List

About Anixa Biosciences Inc

Ticker ANIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,661,700
Market Cap $128M
Description
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...

More about ANIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account